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The expression of virulence determinants in Staphylococcus aureus is controlled by global regulatory loci (e.g.,
sar and agr). The sar locus is composed of three overlapping transcripts (sar P1, P3, and P2 transcripts from
P1, P3, and P2 promoters, respectively), all encoding the 372-bp sarA gene. The level of SarA, the major
regulatory protein, is partially controlled by the differential activation of sar promoters. We previously partially
purified a ⬃12 kDa protein with a DNA-specific column containing a sar P2 promoter fragment. In this study,
the putative gene, designated sarR, was identified and found to encode a 13.6-kDa protein with homology to
SarA. Transcriptional and immunoblot studies revealed the sarR gene to be expressed in other staphylococcal
strains. Recombinant SarR protein bound sar P1, P2, and P3 promoter fragments in gel shift and footprinting
assays. A sarR mutant expressed a higher level of P1 transcript than the parent, as confirmed by promoter
green fluorescent protein fusion assays. As the P1 transcript is the predominant sar transcript, we confirmed
that the sarR mutant expressed more SarA than the parental strain. We thus proposed that SarR is a
regulatory protein that binds to the sar promoters to down-regulate P1 transcription and the ensuing SarA
protein expression.

Staphylococcus aureus is a major human pathogen capable of
causing a wide spectrum of infections ranging from superficial
abscesses, pneumonia, endocarditis, to sepsis (4)). The ability
of S. aureus to cause a multitude of human infections is probably attributable to an impressive array of extracellular and cell
wall-associated virulence determinants that are coordinately
expressed in this organism (35). The coordinate expression of
many of these virulence determinants in S. aureus is regulated
by global regulatory elements such as sar and agr (11, 23).
These regulatory elements, in turn, control the transcription of
a wide variety of unlinked genes, many of which have been
implicated in pathogenesis.
The global regulatory locus agr encodes a two-component,
quorum sensing system that is involved in the generation of
two divergent transcripts, RNAII and RNAIII, from two distinct promoters, P2 and P3, respectively. RNAIII is the regulatory molecule of the agr response and hence responsible for
the up-regulation of extracellular protein production and downregulation of cell wall-associated protein synthesis during the
postexponential phase (20, 34). The RNAII molecule, driven
by the P2 promoter, encodes a four-gene operon, agrBDCA,
with AgrC and AgrA corresponding to the sensor and activator
proteins of a two-component regulatory system. Additionally,
agrD, in concert with agrB, participates in the generation of an
octapeptide with quorum sensing functions (21, 28). The autoinducing peptide would stimulate the transcription of the agr
regulatory molecule RNAIII, which ultimately interacts with
target genes to modulate transcription (34) and possibly translation (31).
In contrast to agr, the sar locus activates the synthesis of both

extracellular (e.g., alpha- and beta-hemolysins) and cell wall
proteins (e.g., fibronectin binding protein) in S. aureus (11).
The sar locus is composed of three overlapping transcripts [sar
P1 [0.56 kb], sar P3 [0.8 kb], and sar P2 [1.2 kb] transcripts),
each with a common 3⬘ end but initiated from three distinct
promoters (P1, P3, and P2 promoters). Due to their overlapping nature, each of these transcripts encodes the major
372-bp sarA gene, yielding the 14.5-kDa SarA protein (2).
DNA footprinting studies revealed that the SarA protein binds
to the promoters of several target genes (14), including agr, hla
(alpha-hemolysin gene), spa (protein A gene), and fnbA (fibronectin binding protein A gene), thus implicating SarA to be
a regulatory molecule that can modulate target gene transcription via both agr-dependent and agr-independent pathways (5,
14, 15). Presumably, with the agr-dependent pathway of target
gene activation, the SarA protein binds to the agr promoter to
stimulate RNAIII transcription; RNAIII, in turn, interacts
with target genes (e.g., hla) to modulate transcription. With the
SarA-dependent but agr-independent pathway, the SarA protein will interact directly with target gene (e.g., hla and spa)
(14) promoters to control gene expression.
Deletion and promoter fusion analyses indicated that the
regions upstream of the sar P2 promoter and between the P1
and P3 promoters may have a modulating role in SarA expression, possibly by controlling transcription from the sar P1 promoter, the predominant promoter within the sar locus (6, 27)
(Fig. 1A). Using a DNA-specific column containing a 49-bp
sequence upstream of the sar P2 promoter that shares homology with the region between the P1 and P3 promoters, we
previously described the purification of a ⬃12-kDa protein
(27). In this study, we report the cloning and sequencing of the
putative 345-bp gene, designated sarR, encoding this DNA
binding protein (predicted molecular size of 13.6 kDa). SarR
shares sequence homology with SarA. Purified recombinant

* Corresponding author. Mailing address: Department of Microbiology Vail 206, Dartmouth Medical School Hanover, NH 03755.
Phone: (603) 650-1340. Fax: (603) 650-1362. E-mail: ambrose.cheung
@dartmouth.edu.
885

886

MANNA AND CHEUNG

INFECT. IMMUN.

FIG. 1. (A) Schematic of the sar promoters and transcripts analyzed in this study. Positions of the transcription start sites (146, 409, and 711
bp upstream of the translation start) for P1, P3, and P2 promoters are depicted according to published sequence (2). The P1, P3, and P2 transcripts
have previously been designated a sarA, sarC, and sarB transcripts. The 49-bp sequence outlined was used to construct a DNA-specific column as
described elsewhere (27). Relative positions of the sar promoter fragments used in gel shift and footprinting studies are indicated (filled boxes);
the promoter fragments for the GFP transcriptional fusion assays are represented by empty boxes. (B) Promoter region of sarR. The transcription
start site has been mapped by primer extension (data not shown) to position 119. The putative ⫺10 and ⫺35 promoter boxes are in bold and
underlined. (C) Alignment of SarR with SarA. Colons represent identity; periods indicate conservative substitutions.

SarR was found to bind to the sar promoters, as confirmed by
gel shift and footprinting studies. Allelic replacement of the
sarR gene with an ermC antibiotic marker disclosed that transcription from the sar P1 and the native P2-P3-P1 promoter, as
determined by flow cytometry and fluorescence spectrophotometric assays, was increased in the sarR mutant compared with
the parental strain. As the P1 transcript is the predominant sar
transcript, we confirmed by immunoblotting that an increase in
sar P1 transcription in the sarR mutant would lead to enhanced
SarA protein expression. Based on the data presented here, we
propose that SarR is a regulatory protein that binds to the sar
promoter region to down-regulate sar P1 transcription and the
ensuing SarA protein expression.

MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains and plasmids
used in this study are listed in Table 1. Phage 11 was used as the transducing
phage for S. aureus strains. S. aureus strain RN4220, a restriction-deficient
derivative of strain 8325-4 (32), was used as the initial recipient for the transformation of plasmid constructs by electroporation, following the protocol of
Schenk and Laddaga (40).
S. aureus cells were grown at 37°C with aeration in CYGP or 03GL broth (32,
33) or tryptic soy broth supplemented with antibiotics when necessary. 03GL and
NYE agar (40) containing antibiotics were routinely used for the selection of S.
aureus transformants; Luria-Bertani medium was used for growing Escherichia
coli. Antibiotics were used at the following concentrations: for S. aureus erythromycin at 5 g/ml, tetracycline at 5 g/ml, and chloramphenicol at 10 g/ml; E.
coli, ampicillin at 50 g/ml, chloramphenicol at 30 g/ml, erythromycin at 200
g/ml, and spectinomycin at 75 g/ml.
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TABLE 1. Strains and plasmids used
Strain or plasmid

S. aureus
RN4220
RN6390
RN6911
ALC488
ALC1713
Cowan I
DB
Newman

Reference or source

32
32
34
9
This study
17
10
29

Comments

Mutant of 8325–4 that accepts foreign DNA
Laboratory strain that maintains its hemolytic pattern when propagated on sheep
erythrocyte agar (parental strain)
agr mutant of RN6390 with ⌬agr::tetM mutation
sar mutant with sarA::ermC mutation
sarR mutant of RN6390 with ⌬sarR::ermC mutation
Laboratory strain
Clinical blood isolate previously used in adhesion and endocarditis studies
Laboratory strain

S. epidermidis

Strain from collection at Utrecht University Hospital

S. haemolyticus

Strain from collection at Utrecht University Hospital

S. saprophyticus

Strain from collection at Utrecht University Hospital

E. coli
XL-1 Blue
DH5␣

26
26

Host strain for cloning
Host strain for cloning

Plasmids
pCR2.1
pBluescript
pUC18
pACYC177
pCL52.1
pET11b
pALC926
pALC1357
pALC1361
pALC1627

Invitrogen
Stratagene
26
New England Biolabs
24
Novagen
This study
This study
This study
This study

E. coli cloning vector for direct cloning of PCR products
E. coli cloning vector
E. coli cloning vector
E. coli cloning vector
Temperature-sensitive E. coli-S. aureus shuttle vector
Expression vector for E. coli
pUC18 containing a 49-bp fragment upstream of the P2 promoter of the sar locus
pET11b containing the 345-bp sarR gene at the NdeI/BamHI site
pACYC177 with a ⬃4-kb ClaI fragment containing the sarR region of RN6390
pBluescript with a 2.5-kb EcoRI/ClaI fragment containing the sarR gene subcloned
from pALC1361
pBluescript with a 290-bp deletion of the sarR gene in pALC1627
pCL52.1 with a 290-bp sarR deletion replaced by the ermC gene at the EcoRV/SalI site

pALC1687
pALC1696

This study
This study

Cloning of the sarR gene and construction of the sarR mutant. In a previous
study (27), we partially purified the SarR protein by using a DNA-specific
column containing a 49-bp DNA fragment (nucleotides [nt] 71 to 119) covalently
linked to Sepharose (13). The first 14 residues in the amino terminus were
determined by microsequencing at the core facility at our institution. A BLAST
search of the S. aureus genome data bank at the Institute for Genomic Research
(TIGR) revealed a partial open reading frame (ORF) of 47 amino acids. Using
these data, we successfully amplified by PCR a 141-bp fragment with two degenerate oligonucleotides, 5⬘-ATG(T/A)(C/G)(A/T)AAAAT(T/C)AA(T/C)GA
TAT(T/C)AA(T/C)GATTTT-3⬘ and 5⬘-ATT(T/A)G/C(A/T)(T/C)TC(T/A)(G/
C)(A/T)(A/T)C(G/T)(T/C)AA(A/G)AT(A/G)TG(A/G)TT(T/C)AA-3⬘.
The
PCR fragment was cloned into the vector pCR2.1 (Invitrogen). Southern hybridization of enzyme-restricted chromosomal DNA of the parental strain RN6390
with a radiolabeled 141-bp DNA probe revealed a single ⬃4-kb ClaI-digested
hybridizing fragment. To clone this fragment, ClaI-digested chromosomal DNA
in the range of 3 to 5 kb was resolved in an agarose gel, excised, purified, and
ligated to the ClaI site of pACYC177 in E. coli DH5␣. Positive-reacting clones,
all containing the ⬃4-kb ClaI fragment, were identified. Sequencing of one of
these clones revealed a 345-bp ORF with identity to the partial 47-amino-acid
sequence of SarR as predicted from the S. aureus genome.
Deletion and insertion mutagenesis was performed with a Stratagene Quick
Change kit to introduce a deletion and a mutation concomitantly into the sarR
gene. In brief, the ⬃4-kb ClaI DNA fragment containing the sarR gene in
recombinant pACYC177 was cloned into pBluescript to serve as a template for
mutagenesis. An oligonucleotide (5⬘-22GCATGAAAAAGA[T]TATC[T]GGGC
ATTT45-338GTGAGTCTAACGAT[A]ATCTCATCTAAA363-3⬘ [native nucleotides are indicated in brackets]), and its complement were used to construct a
deletion and to introduce an exogenous EcoRV restriction site into the sarR gene
(restriction site underlined: intact sarR gene from nt 208 to 555). After amplification with the recombinant pBluescript template, the PCR product was digested

with DpnI to remove methylated template DNA (i.e., pBluescript with the native
sarR gene) and transformed into XL1-Blue cells to select for ampicillin-resistant
colonies. Successful deletion and mutation in the resultant clones were confirmed by restriction analysis with EcoRV and finally verified by automated DNA
sequencing. The ermC gene was then ligated to the EcoRV site of the mutated
construct. The fragment containing an ermC replacement of the sarR gene was
cloned into the temperature-sensitive shuttle vector pCL52.1 (39), which was
then transformed into RN4220 by electroporation (40) followed by transduction
into RN6390 with phage 11 as described elsewhere (11). Transductants were
selected at 30°C on erythromycin- and tetracycline-containing plates.
S. aureus RN6390 harboring the recombinant pCL52.1 was grown overnight at
30°C in liquid medium in the presence of erythromycin, diluted 1:1,000 in fresh
medium, and propagated at 42°C, a temperature nonpermissive for the replication of pCL52.1. This cycle was repeated four times, and the cells were replicate
plated onto 03GL plates containing erythromycin and erythromycin plus tetracycline to select for tetracycline-sensitive but erythromycin-resistant colonies,
representing mutants with double crossovers. The mutations were confirmed by
Southern hybridization with sarR and ermC probes.
Southern blot hybridization. Chromosomal DNA of assorted staphylococcal
species was isolated from lysostaphin-treated cells as previously described (11),
restriction digested, resolved in agarose gels, and transferred onto a Hybond N⫹
membrane (Amersham, Arlington Heights, III.). Hybridization was performed
under high-stringency conditions with 32P-labeled DNA probes as described
elsewhere (11). The blots were subsequently washed and autoradiographed.
Purification of proteins. The intact 345-bp sarR gene was amplified by PCR
using RN6390 chromosomal DNA as the template and primers containing flanking restriction sites (NdeI and BamHI) to facilitate cloning into expression vector
pET11b (Novagen). The recombinant plasmid containing the sarR gene was
transformed to E. coli BL21(DE3)pLysS. Enhanced expression of SarR was
induced by adding IPTG (isopropyl-1-thio-␤-D-galactopyranoside) to a 2-liter
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growing culture (37°C) at an optical density at 650 mm (OD650 of 0.7. After 4 h
of additional growth, cells were harvested, resuspended in buffer (25 mM Tris-Cl,
1 mM EDTA) [pH 8.0], 100 mM NaCl, 10% sucrose, 1 mM dithiothreitol
[DTT]), flash-frozen and thawed twice, and clarified by centrifugation at 4°C
(45,000 rpm for 1 h). After precipitation with 80% ammonium sulfate, the pellets
were dissolved in bufferA (10 mM Tris-Cl [pH 7.5], 1 mM EDTA, 100 mM NaCl,
10% glycerol, 1 mM DTT), dialyzed against buffer A, and applied to a Resource-Q column in an AKTA purifier (Pharmacia, Piscataway, N.J.). The
flowthrough was reapplied to a Resource-S column and eluted with a NaCl
gradient. The fractions were analyzed in a sodium dodecyl sulfate (SDS)–12%
polyacrylamide gel. Fractions containing the putative SarR protein were pooled,
dialyzed against buffer A with 40% glycerol, and stored at ⫺80°C. The authenticity of the SarR protein was confirmed by determining the N-terminal 15
residues with microsequencing. The concentration of the purified protein was
determined with the Bio-Rad protein assay solution (Bio-Rad Laboratories,
Richmond, Calif.), using bovine serum albumin as the standard.
Production of anti-SarR monoclonal antibodies. Purified SarR protein was
used to immunize two (BALB/c ⫻ SJL/J)F1 mice (100 g of each) to obtain
monoclonal antibodies as described elsewhere (22). The titers of the immune
sera were determined by an enzyme-linked immunosorbent assay (ELISA) in
which diluted sera were added to microtiter wells precoated with SarR (5 g/ml)
as described by Jones et al. (22). After splenic fusion, antibodies from limited
dilutions were screened by an ELISA with immobilized SarR protein. Monoclonal antibodies were then purified from culture supernatants with a protein
A-agarose column as described previously (22).
RNA isolation and Northern analysis. Overnight cultures of S. aureus were
diluted 1:50 in CYGP broth with appropriate antibiotics and grown to mid-log
(OD650 ⫽ 0.7 with an 18 mm borosilicate glass tube), late log (OD650 ⫽ 1.1), and
postexponential (OD650 ⫽ 1.7) phases. The cells were pelleted and processed
with 1 ml of Trizol (Gibco-BRL, Gaithersburg, Md.) in combination with 0.1mm-diameter sirconia-silica beads in a Fast Prep reciprocating shaker (Bio 101,
San Diego, Calif.) as described elsewhere (8). Ten micrograms of total cellular
RNA from each sample was electrophoresed through a 1.5% agarose–0.66 M
formaldehyde gel in MOPS (morpholinepropanesulfonic acid) running buffer (20
mM MOPS, 10 mM sodium acetate, 2 mM EDTA [pH 7.2]). RNA was transferred onto Hybond N⫹ membranes (Amersham) under mild alkaline conditions
by using a Turboblotter system (Schleicher Schuell, Keene, N.H.) as described by
the manufacturer. RNA was fixed to the membrane by baking at 80°C for 1 h. For
detection of specific transcripts, gel-purified DNA probes were radiolabeled with
[32P] dCTP by using the random-primed method (Ready-To-Go labeling kit;
Pharmacia) and hybridized under aqueous conditions at 65°C. The blots were
subsequently washed and autoradiographed.
Promoter fusion analysis with the gfpuvr reporter gene. To confirm the effect
of the sarR mutation on sar promoter activities, we cloned sar promoter fragments (P1, P2, P3, and combined P2-P3-P1) (27) into shuttle vector pALC1484,
which is a derivative of pSK236 containing the recombinant gfpuvr gene. Briefly,
the gfpuvr gene was constructed by introducing a S65T mutation into gfpuv (Clontech, Palo Alto, Calif.), thereby facilitating a shift in the excitation maxima from
395 to 488 nm (19). The sar promoter fragments were then cloned into pALC1484,
upstream of the gfpuvr reporter gene. After sequence confirmation, the recombinant
pALC1484s were then electroporated into RN4220 and transduced into S. aureus
strains RN6390 and its isogenic sarR mutant (11).
The activities of sar promoter fragments linked to the gfpuvr reporter gene in
RN6390 and its isogenic sarR mutant were assayed by flow cytometry. Bacterial
cell suspensions obtained at different parts of the growth cycle were analyzed by
fluorescence-activated cell sorting (FACS) in a FACScan (Becton Dickinson,
Franklin Lakes, N.I.). After filtering of bacterial samples through a 5-m-poresize filter to remove large aggregates, bacteria were detected by side scatter as
described by Russo-Marie et al. (38). Fluorescence and side scatter data were
collected with logarithmic amplifiers. The fluorescence data were reported in
fluorescence units as specified by the FACScan.
To obtain more quantitative fluorescence data, each of the above gfpuvr reporter constructs was diluted 1:100 from overnight cultures into fresh CYGP
medium and, beginning at the second hour, sampled hourly (200 l) for 10 h to
encompass the growth cycle from log to stationary phases. The samples were
analyzed for total fluorescence and OD605 in microtiter wells in a multi purpose
fluorescence spectrophotometer (FL600; BioTek Instruments, Winooski, Vt.).
The fluorescence units and ODs were recorded as given by the instrument. The
background was ⬃200 to 300 fluorescence units, with variations of less than 100
units between duplicate samples.
Cell extract preparation and Western analysis. Cell extracts from mid-log, late
log, and early stationary phases (representing OD650 of 0.7, 1.1, and 1.7, respectively, in an 18-mm borosilicate tube) were prepared from RN6390, the isogenic
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sarR mutant, and other staphylococcal strains. Cells were grown in CYGP broth
(50 ml) supplemented with the appropriate antibiotics. After pelleting, the cells
were resuspended in 0.5 ml of TEG buffer (25 mM Tris-HCl, 5 mM EGTA [pH
8.0], and cell extracts were prepared from lysostaphin-treated cells as described
by Mahmood and Khan (25).
Equivalent amounts of cellular proteins were separated in SDS–12% polyacrylamide gels and transferred onto nitrocellulose membranes as described
elsewhere (41). The blots were incubated at room temperature (RT) with a
1:1,000 or 1:2,000 dilution of anti-SarR or anti-SarA monoclonal antibody for
3 h, followed by another hour of incubation with a 1:10,000 dilution of goat
anti-mouse alkaline phosphatase conjugate (Jackson ImmunoResearch, West
Grove, Pa.). Immunoreactive bands were detected as described by Blake et al.
(3). SeaBlue-prestained protein standards (Novex, San Diego, Calif.) were used
for molecular weight estimations.
Gel shift analysis and DNase I footprinting. Gel shift assays were performed
to determine the interaction of purified SarR with sar promoters. DNA fragments were end labeled with [␥-32P] ATP by using polynucleotide kinase. Labeled DNA fragments were incubated at RT for 20 min with the indicated
amounts of purified protein in 25 l of binding buffer (25 mM Tris-HCl) [pH
7.5], 0.1 mM EDTA, 75 mM NaCl, 1 mM DTT, 5% glycerol) containing 0.5 g
of calf thymus DNA. The reaction mixtures were analyzed by nondenaturing
polyacrylamide gel electrophoresis as described elsewhere (14). The band shifts
were detected by exposing dried gels to film.
Footprinting assays with linear DNA template and DNase I were performed
using a modification of the method previously described (16). A 49-bp fragment
upstream of the sar P2 promoter region (27) was cloned into the BamHI site of
pUC18, yielding pALC926. A 109-bp EcoRI/HindIII fragment from pALC926
was gel purified and end labeled with ␥-32P. PCR fragments containing sar P1 (nt
531 to 859 and 620 to 859) and P3 (nt 364 to 525) promoter regions were also
used in footprinting reactions. To label these PCR products, only one of the
primers was end labeled with ␥-32P in the amplification reactions, yielding PCR
products labeled at one end. For the assay, the binding reactions were carried out
in a 100-l reaction volume containing 20 mM Tris-HCl (pH 8.0), 100 mM NaCl,
5 mM MgCl2, 1 mM CaCl2, 2 mM DTT, 10 g of Borine serum albumin, 0.4 g
of calf thymus DNA, template DNA, and various amounts of the SarR protein
at RT for 30 min. DNase I (0.02 U; Boehringer Mannheim, Indianapolis, Ind.)
was added and allowed to incubate for 1 min at RT. The reaction mixtures were
then extracted with phenol-chloroform. DNA was ethanol precipitated, resuspended in loading buffer (98% formamide, 10 mM EDTA [pH 8.0], 0.025%
[wt/vol] xylene cyanol FF, 0.025% [wt/vol] bromophenol blue), and analyzed on
a 6% denaturing polyacrylamide sequencing gel. Positions of the protected
regions were identified by comparing the footprint with the A⫹G sequencing
ladder of the same fragment (26).
Nucleotide sequence accession number. The sarR sequence has been assigned.
GenBank accession no. AF207707.

RESULTS
In a previous study, we demonstrated that the sar promoters
are differentially expressed during the growth cycle, with P1
and P2 promoters being most active during the exponential
phase and the P3 promoter activated postexponentially (27).
Because of the complexity in promoter activation and the ensuing expression of SarA, we previously hypothesized that the
promoter region upstream of the sarA gene may serve as a
binding site for one or more trans-acting factors (2, 27). Taking
advantage of a P2 promoter sequence (2) that shares homology
with a region upstream of the sar P1 promoter (Fig. 1A), we
previously used a DNA-specific column, containing the 49-bp
P2 promoter sequence, to partially purify a ⬃12-kDa protein
that bound to sar promoter fragments (27). To further characterize this protein and investigate its regulatory function, we
report here the cloning and characterization of the sarR gene
product, using biochemical, immunological, and genetic approaches.
Cloning and sequence analysis of the sarR gene encoding a
13.6-kDa protein. To identify the gene encoding SarR, we
blotted the ⬃12-kDa protein onto a polyvinylidene difluoride
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membrane for N-terminal sequencing. The first 14 amino acids
were X(K)IND(I)NDLVNA(S/T)F (X is an unknown residue;
residues in parentheses are putative). In searching the data
bank of the S. aureus genome (www.tiger.org), we obtained a
partial ORF of 47-amino-acid sequence that corresponds to
the N-terminal sequence of the ⬃12-kDa protein. By using two
degenerate oligonucleotides of 30 bases each, we amplified a
141-bp fragment to probe a chromosomal digest of S. aureus
strain RN6390 (data not shown), thus allowing us to identify a
⬃4-kb ClaI-hybridizing fragment. A plasmid DNA library containing ⬃3- to 5-kb ClaI fragments constructed in pACYC177
(26) was then screened with the 141-bp PCR-generated probe.
A positive clone (pALC1361) yielding a ⬃4-kb insert at the
ClaI site of pACYC177 vector was identified. In determining
the sequence of the insert and comparing the insert sequence
with that of the 141-bp probe, we were able to obtain the DNA
sequence of the putative gene, which we called sarR (Fig. 1B).
The predicted SarR protein contains 115 amino acids, with a
predominance of charged residues (34%) and a predicted molecular size of 13,689 Da. The sarR gene has a putative ShineDalgarno sequence (AGGAGTGG) lying 7 bp upstream of the
translation start, with typical initiation (ATG) and termination
(TAA) condons. To ascertain the transcription start site and
the putative promoter boxes, we mapped the 5⬘ end of the sarR
transcript by primer extension, using an internal primer of the
noncoding strand positioned near the N terminus of the sarR
coding region (data not shown). The transcription initiation
site is located 88 bp upstream of the translation start, thereby
allowing us to identify the putative -10 and -35 promoter boxes
as TAGAAT and TTACCG, respectively (Fig. 1B).
In searching the GenBank database for related proteins, we
found that the entire SarR protein shares sequence similarity
with SarA, with a high probability score of 1.8e⫺7 (Fig. 1C).
There were also other SarR homologs in the S. aureus database
(University of Oklahoma S. aureus genome database). Like
SarA, the SarR protein has a deduced basic pI (9.23). The
sequence similarity between SarR and SarA is 51%, with 28%
identity (Fig. 1C). In limiting the homology to specific regions,
we found that residues 52 to 75 of SarR share homology with
residues 54 to 77 of SarA, which, in turn, have a limited but
regional sequence similarity to the DNA binding domain of
VirF (residues 175 to 198), a transcription regulator of virulence gene expression in Shigella flexneri (13, 18).
Overexpression of SarR and production of monoclonal antibodies. To obtain a large amount of SarR for our studies, we
cloned the sarR gene into pET11b and over expressed the gene
product under an IPTG-inducible promoter in E. coli BL21.
The expression, purification, and purity of the SarR protein are
shown in Fig. 2. The SarR protein was expressed primarily in
the cytosolic fraction (Fig. 2, lane 2). After 80% ammonium
sulfate precipitation (Fig. 2, lane 5), the redissolved proteins
were dialyzed and applied to an anion-exchange column (Resource-Q; Pharmacia), only to be found in the flowthrough
(Fig. 2, lane 6). The flowthrough was then applied to a cationexchange column (Resource-S; Pharmacia) and eluted with a
salt gradient (see Materials and Methods for details). Using
this purification scheme, we were able to purify SarR to near
homogeneity (Fig. 2, lane 8). The authenticity of SarR was
confirmed by N-terminal sequencing. The purified SarR was
then used to immunize mice for the production of anti-SarR
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FIG. 2. Purification of SarR from the pET11b expression vector.
Equivalent volumes of protein fractions obtained during the purification process were applied to an SDS–12% polyacrylamide gel. Lane 1,
whole-cell lysate of E. coli containing pALC1357 (pET11b with the
sarR gene); lane 2, supernatant of the cell lysate after clarification by
centrifugation; lane 3, supernatant before 40% ammonium sulfate
precipitation; lane 4, pellet resulting from 40% ammonium sulfate
precipitation; lane 5, pellet from 80% ammonium sulfate precipitation;
lane 6, flowthrough of the redissolved 80% ammonium sulfate precipitant as applied to a MonoQ column (Pharmacia); lane 7, flowthrough
from the MonoS column (Pharmacia); lane 8, NaCl elution from the
MonoS column. N-terminal sequencing confirmed the identity of the
purified SarR protein.

monoclonal antibodies. Three monoclonal antibodies, designated 2A7, 2C7, and 5E4, were obtained. Despite the similarity
between SarR and SarA, cross-reactive studies indicated that
anti-SarR monoclonal antibodies reacted with SarR and not
SarA on immunoblots (data not shown).
Evidence for the existence of sarR in other staphylococcal
strains. To examine whether the sarR gene is present in a
variety of S. aureus strains and in other staphylococcal species,
we analyzed S. aureus strains RN6390, Newman, Cowan I (17),
and DB (12) and one clinical isolate each of S. epidermidis, S.
haemolyticus, and S. saprophyticus (from Utrecht University
Hospital, Utrecht, The Netherlands) by PCR, Southern,
Northern, and immunoblot analyses (Fig. 3). PCR analysis of
these strains revealed the presence of the sarR gene in all four
S. aureus isolates as well as in S. saprophyticus. Surprisingly, the
⬃380-bp fragment was missing in products of PCRs with chromosomal DNA templates of S. epidermidis and S. haemolyticus
(Fig. 3A). Southern blot analysis also confirmed the results of
the PCRs with a ⬃4-kb ClaI fragment hybridizing to the sarR
probe (Fig. 3B). Northern blot analyses were also performed to
assess the expression of the sarR transcript in these strains. In
accord with the PCR and Southern blot data, the sarR transcript was detected in all staphylococcal strains except S. epidermidis and S. haemolyticus (Fig. 3C). Additional Northern
analysis with S. aureus strain RN6390 indicated that the transcription of sarR peaked during the postexponential phase (see
below). Notably, the size of the sarR transcript was ⬃0.4 kb,
suggesting that the transcript is likely to be monocistronic. To
correlate gene transcription with protein expression, we
probed for the presence of SarR in these strains by immunoblotting. For this experiment, equivalent amounts of cell extracts of various strains (25 g of protein each) harvested from
stationary phase cultures were blotted onto nitrocellulose and
probed with anti-SarR monoclonal antibody followed by goat
anti-mouse alkaline phosphatase conjugate. As anticipated, a
band corresponding to ⬃14 kDa was detected in S. aureus
strains RN6390, DB, Cowan I, and Newman and a clinical
isolate of S. saprophyticus. As with the Northern blot data,
SarR protein was not expressed in the S. epidermidis and S.
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FIG. 3. PCR amplification of sarR-like genes in S. aureus strains
RN6390, Cowan I, DB, and Newman, S. epidermidis, S. haemolyticus,
and S. saprophyticus using primers 5⬘-208ATGAGTAAAATTAATGA
TATTAAT231-3⬘ and 5⬘-589TCGTTCAATGTTATTAAACG569-3⬘.
(B) Southern blot of the above strains, restricted with ClaI and probed
with a 345-bp sarR probe (nt 208 to 552). (C) Northern blot of total
cellular RNA (10 g each) of the above strains, probed with a sarR
probe. (D) Cell lysates of the above strains, immunoblotted onto
nitrocellulose and probed with anti-SarR monoclonal antibody 2A7 at
a 1:2,000 dilution.

haemolyticus isolates (Fig. 3D). Collectively, these results suggested that the sarR gene is actively transcribed in S. aureus
and a clinical isolate of S. saprophyticus but not in S. epidermidis and S. haemolyticus. More importantly, the expression of
SarR correlates with gene transcription. Nevertheless, our data
did not eliminate the possibility that the sarR homologs in S.
epidermidis and S. haemolyticus may be too divergent from the
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S. aureus counterpart and hence would not be detectable under
high-stringency conditions.
Binding of SarR to sar promoter fragments by gel shift and
footprinting assays. Recognizing SarR binds to the sar P2 promoter region (2, 27), we examined the interaction between
SarR and various sar promoter fragments with gel shift and
footprinting assays. Accordingly, purified recombinant SarR
from E. coli was used in gel shift assays with assorted DNA
fragments of the sar promoter region including P2 (nt 1 to 196
[2]) P3 (nt 364 to 525), and P1 (nt 531 to 859). As expected, the
mobility of the labeled DNA fragments became more hindered
with increasing concentrations of SarR in gel shift assays (Fig.
4). The unusual laddering pattern of the band shifts was observed with all three sar promoter fragments. One plausible
explanation is that each of the sar promoter fragments may
contain multiple binding sites; alternatively, the binding of
SarR in multimeric form to a common site or multiple sites
within each of the sar promoter fragment may be plausible.
Detailed stoichiometric studies to ascertain these possibilities
are in progress. A comparison of the relative binding of SarR
and SarA to the sar P1 promoter is of interest. More specifically, the amount of SarA required to completely retard the
mobility of 2 to 5 ng of radiolabeled sar P1 fragment was 10
times more than that of SarR, thus indicating the higher avidity
of SarR than SarA for the sar P1 promoter fragment (data not
shown).
To determine the binding site of SarR and verify the specificity of binding to the sar promoter region, DNase I footprinting analysis was performed. To identify the SarR binding site,
a 109-bp EcoRI-HindIII fragment derived from pUC18 containing the 49-bp sequence (27) was end labeled at the EcoRI
or HindIII site separately and subjected to DNase I footprinting with various concentrations of SarR. Analysis of the footprint of the plus strand (EcoRI site end labeled) (Fig. 5A)
disclosed the protected region (nt 81TAAATTAATGTTATT
TTTTAATAATTTA108) (2) to be extremely AT rich (96%),
thus implying specific binding of SarR to this region but not to
the more GC-rich polylinker region of pUC18, even when
higher concentrations of SarR were used in the assay. A similar
protection site was also found for the minus strand (HindIII
site end labeled) (data not shown). The SarR protected region
was found to consist of a 7- to 8-base sequence (TAAATTAA,
with the last base variable) conserved in both strands (e.g.,

FIG. 4. Gel shift assay of end-labeled 32P fragment of sar P1 (nt 531 to 859) 2, P2 (nt 1 to 196), and P3 (nt 364 to 525) promoters. Increasing
amounts (30, 60, 100, 150, 200, 250, and 300 ng) of purified SarR were applied to the reaction mixtures. In competition assays, 50- and 100-fold
excesses of unlabeled DNA fragments were added.

VOL. 69, 2001

CHARACTERIZATION OF sarR IN S. AUREUS

891

FIG. 5. DNase I footprinting assays of SarR with end-labeled 32P sar P2 (49-bp fragment), P1 (nt 531 to 859), and P1⬘ (nt 620 to 859) promoter
fragments. The sequence was deduced from G⫹A ladder reactions run in parallel by the standard method (26). The following amounts of SarR
were applied to the sar P2 and P1 reactions: 30, 60, and 100 ng. With sar P1⬘, only lanes containing 30 and 60 ng of SarR protein are shown. The
binding site of SarR on the sar P3 promoter (underlined) was also mapped: 373 TTACTAAATTAAAAAAATTA402 (footprinting data not shown)
(2). The underlined nucleotides represent the 7- or 8-base sequence conserved in the binding site throughout the sar promoter region.

101

ATAATTTA108 being the complement of TAAATTAA)
and throughout the sar promoter region (27).
We also determined the binding of SarR to other sar promoter regions. In a previous study (27), we had shown that an
inverted repeat region (nt 553 to 593) upstream of the sar P1
promoter may play a role in repressing sar P1 transcription.
Recognizing that SarR binds to a large P1 fragment in gel shift
assays (Fig. 4), we performed footprinting analysis with two
different DNA fragments upstream of the sar P1 promoter
(329 bp [nt 531 to 859] and 240 bp [nt 620 to 859] [2]). Using
32
P-end-labeled sense strand, the SarR-protected region on
the 329-bp sar P1 promoter fragment was found to comprise
several regions including nt 551 to 553, 556 to 575, 582 to 603
(586TAAATTAT593), and 620 to 640 (Fig. 5B). In analyzing the
smaller 240-bp P1 fragment, four additional protected regions,
downstream of the above binding sites, were uncovered: nt 633
to 640, 643 to 667, 673 to 678, and 687 to 708 (Fig. 5C). Thus,
the inverted repeat region (nt 553 to 593), which has previously
been shown to play a putative role in repressing P1 transcription (27), is also part of the SarR binding sites. We also uncovered the SarR binding site on the sar P3 promoter: 373TT
ACTAAATTAAAAAAATTA402 (footprinting data not shown)
(2). In comparing the broad binding sites protected by SarR, a
common feature is their highly AT-rich nature. More remarkably, the 7- to 8-bp conserved sequence (TAAATTAA) was
included within the SarR binding sites in each of the sar promoter fragments (P2, P1, and P3).
Expression of the sarR gene in RN6390 and its isogenic sar
and agr mutants. During the growth cycle, the major sar gene
product such as SarA partially mediates its effect by binding to

the agr promoter to influence RNAII and RNAIII transcription. To ascertain if the sarR gene is modulated by sar or agr
(i.e., acting downstream of the sar or agr regulatory cascade),
we assayed for sarR transcription in parental strain RN6390
and its isogenic agr and sar mutants. To ensure that comparable amounts of total cellular RNA were applied to each lane,
we compared rRNA bands stained with ethidium bromide
among the lanes (Fig. 6A). As displayed in Fig. 6B, the transcription of sarR in RN6390 could be detected in mid-log phase
and was maximally expressed during the postexponential
phase. Accounting for minor experimental variations, the observation that sarR transcription was not significantly altered in
sar and agr mutants indicated that sar and agr did not regulate
sarR as one would expect if these loci lie downstream of the
sarR regulatory cascade. This notion was support by the finding
(described below) that a mutation in sarR affects sar and agr
transcriptions.
We also determined the expression of the SarR protein
during the growth cycle by immunoblotting. Using anti-SarR
monoclonal antibody 2C7 (1:1,000 dilution), we probed an
immunoblot of cell extracts of RN6390 derived from cells
grown to late-log (OD650 ⫽ 1.1) and postexponential
(OD650 ⫽ 1.7) phases. Employing ⬃25 g of cellular proteins
in each lane, we found that the expression of SarR corresponded quite well with the pattern of sarR transcription, with
SarR expression detectable at late log phase and maximal
during the postexponential phase (Fig. 6C).
Expression of sar in a sarR mutant. Aware that the SarR
protein likely modulates SarA expression by virtue of its binding to the sar promoter region, we proceeded to construct a
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FIG. 6. Expression of sarR in parental strain RN6390 and its sar
(ALC488) and agr (RN6911) mutants. (A) Northern blots of sarR
transcript in RN6390 and its isogenic sar and agr mutants. Ten micrograms of total cellular RNA was applied to each lane. The sarR probe
was a 345-bp fragment (nt 208 to 552). OD650 of 0.7, 1.1, and 1.7
represent mid-log, late log, and early stationary phases, respectively, as
predicted from the growth cycle. (B) Ethidium bromide stain of the
above RNA gel prior to transfer to a hybridization membrane. (C)
Expression of SarR on an immunoblot probed with anti-SarR antibody
2C7. Each lane contains 25 g of cell extract of RN6390 grown to late
log and early stationary phases. Cells at mid-log phase expressed little
SarR; as expected, SarR was not detected in the sarR mutant ALC1713
(data not shown). The positive control lane contains 0.1 g of purified
SarR protein.

sarR deletion mutant by replacing the sarR gene with an ermC
gene in strain RN6390 (see Materials and Methods). Northern
analysis confirmed that the transcription of sarR was disrupted
in sarR mutant ALC1713 (data not shown). To analyze the
effect of sarR on individual sar promoters, we cloned P2 (nt 1
to 180 plus 197 bp upstream), P3 (nt 364 to 525), P1 (nt 620 to
859), and combined (or native) P2-P3-P1 promoter (nt 1 to 859
plus 197 bp upstream) (2, 27) upstream of the gfpuvr reporter
gene in shuttle plasmid pALC1484. Using flow cytometry to
evaluate promoter activity, we found that the sar P1 and combined P2-P3-P1 promoters were more active in the sarR mutant
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than the parental control (mean fluorescence of 5.01 ⫾ 0.29
[log scale] in RN6390 versus 5.84 ⫾ 0.13 in the sarR mutant
and 5.49 ⫾ 0.21 in RN6390 versus 8.44 ⫾ 0.24 in the mutant,
for P1 and combined promoters, respectively, during the postexponential phase). However, the relative weakness of the sar
P3 and P2 promoters compared with the P1 promoter (⬃20- to
30-fold less than P1) (27), coupled with the relative stability of
the green fluorescent protein (GFP) reporter, rendered flow
cytometry less useful to record small variations in GFP expression during the growth cycle among 10,000 organisms gated for
this experiment. Not surprisingly, we failed to detect differences in activation of the weaker sar P3 and P2 promoters
between the parent and the isogenic sarR mutant by flow cytometry (27). More specifically, the level of P2 and P3 activation as detected by flow cytometry was only slightly above
background levels (data not shown).
To obtain more quantitative fluorescence data for a larger
number of bacterial cells, we used a multifunction fluorescence
spectrophotometer in a microtiter format (FL600; BioTek Instruments) to measure the OD and total fluorescence of samples (200 l) obtained serially during the growth cycle. To
minimize the variation in fluorescence attributable to cell density, we plotted fluorescence per OD unit against OD over a
10-h period (extending from log to stationary phase). The data
showed that the sar P1-GFP fusion activity in the sarR mutant
was higher than that in the parental strain (RN6390) throughout the growth cycle (Fig. 7A). The early decline in fluorescence for both strains is likely attributable to the carryover of
the GFP from the overnight inoculum. Following the decline,
the highest level of GFP fusion in the mutant occurred late in
the stationary phase (at⬃7 to 10 h after initial culture dilution)
(Fig. 7A), at a time when the sarR transcript level and the
expression of SarR in the parent were highest (Fig. 6B and C).
Curiously, the level of GFP fusion for the sar P1 promoter in
the parental strain declined after the initial dilution, but was
higher than the background (⬃300 fluorescence units), during
the growth cycle. This finding is likely attributable to a steady
decrease in P1 promoter activation (per bacterial cell) in the
parental strain as the cell cycle progressed (Fig. 7A). Additionally, a lack of contribution from upstream promoters (i.e., P3
and P2) to modulate P1 activity in this promoter fragment may
conceivably play a role. Similar studies were also conducted for
the combined or native sar P2-P3-P1 promoter linked to the
gfpuvr reporter. In this instance, the combined promoter activity
in the sarR mutant was also higher than that of the parent (Fig.
7B). As with the P1 promoter, the level of activity for the
combined promoter decreased after initial culture dilution for
both strains and then increased during the postexponential
phase. Of interest, the increase in combined promoter activity
with growth in the parental strain seemed to suggest that the
sequence element upstream of P1 may have contributed to the
overall increase in combined promoter activity during the postexponential phase. However, we were not able to demonstrate
any differences in fluorescence for the P2 or P3 promoter GFP
fusion between the sarR mutant and its isogenic parent. Notably, the fluorescence of the P2 and P3 promoters was only
slightly above background; thus the fluorescent assays may not
be sensitive enough to detect subtle differences in P2 and P3
promoter activities.
As the P1 transcript is the predominant sar transcript (27),
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FIG. 8. Effect of the sarR mutation on SarA and agr expression. (A)
SarA expression during mid-log, late log, and early stationary phases;
(B) agrA (RNAII) transcription. (A) Immunoblot of cell extracts (5 g
of protein each) of RN6390 and the sarR mutant (harvested at mid-log,
late log, and stationary phases) probed with anti-SarA monoclonal
antibody 1D1 at 1:2,000 dilution. The positive control lane contains 0.5
g of purified SarA. Similar results were obtained with 25 g of
protein per lane. (B) Northern blot of the RNAII (agrA probe) transcript in RN6390 and the sarR mutant (10 g of total RNA each). The
agrA probe corresponds to nt 3830 to 4342 according to the published
sequence 23.
FIG. 7. Promoter activation of sar P1 and combined P2-P3-P1 promoters fused to a gfpuvr reporter gene as evaluated in a fluorescence
spectrophotometer (FL600; BioTek Instruments). (A) Recombinant
shuttle plasmid pALC1484 containing the sar P1 promoter linked to
gfpuvr (excitation maxima at 488 nm) was introduced into strain
RN6390 (䉬) and its isogenic sarR mutant ALC1713 (䡲). A negative
control (RN6390 containing pALC1484 with no promoter fragment)
showed no significant background fluorescence (background ⫽ ⬃300
fluorescence units [data not shown]). Cells were obtained hourly (200
l of each in duplicate) during the growth cycle (from h 2 to 10 after
an initial dilution of 1:100 in fresh medium) to obtain fluorescence and
OD values in the same instrument. To minimize variations in fluorescence attributable to cell density, the data are presented as average of
reported fluorescence per OD unit in triplicate samples plotted against
the mean OD. The error bar was too small to be discerned (typically
less than 100 fluorescence units). The experiment was repeated at least
thrice; one representative experiment is shown. (B) Plot similar to that
in panel A except that the combined sar P2-P3-P1 promoter fragment
was used in place of the P1 promoter in the recombinant pALC1484
containing the gfpuvr reporter gene. In similar assays with the individual
sar P2 and P3 promoters linked to the gfpuvr reporter in the isogenic
pair, we detected no differences in GFPuvr expression between the
parental strain and the sarR mutant. However, the level of fluorescence
associated with individual P2 and P3 promoters was very low and only
slightly above background levels.

we reasoned that an intact sarR gene may repress the expression of SarA, the major sar regulatory molecule. Accordingly,
we obtained cell extracts of the isogenic sarR strains during
various stages of the growth cycle. Using cell extracts (25 g of
protein each) of the sarR mutant obtained at different phases
of the growth cycle, we probed an immunoblot with anti-SarA
monoclonal antibody 1D1 (15). As shown in Fig. 8A, the sarR
mutant expressed higher levels of SarA protein than the isogenic parent at ODs representing mid-log, late log, and sta-

tionary phases. Notably, in both the parental and mutant
strains, SarA expression was maximal during the late log phase
and tapered toward the stationary phase. Presumably, the reduction in SarA expression in the parental strain during the
stationary phase may be partially explained by increased proteolytic activity and hence processing of SarA in stationary
cells (27, 35). Additional immunoblot analyses with increased
amounts of cell extracts (at 25 g each) from mid-log, late log,
and stationary phases also confirmed higher expression of
SarA in the sarR mutant than in the parental strain (data not
shown). Taken together, these data support our original hypothesis that SarR is likely a DNA binding protein that binds
to the sar promoter to down-regulate SarA expression.
In a prior study, we showed that the level of SarA correlates
with the extent of agr activation (15). Based on our data on
SarA expression in sarR mutant ALC1713, we predicted that
transcription of RNAII of agr would be enhanced in a sarR
mutant compared with the parental strain. Northern analysis of
sarR mutant ALC1713 with an agrA (RNAII) probe confirmed
this prediction (Fig. 8B). Collectively, these data supported the
notion that SarR likely down-regulates SarA expression, probably by binding to the sar promoter to down-modulate sar P1
transcription, resulting in the modulation of target genes (e.g.,
agr) downstream of the sar regulatory cascade.
DISCUSSION
The sar locus is characterized by a 372-bp sarA ORF the
expression of which is partially controlled by the sar triplepromoter system. Within the triple-promoter region are mul-
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tiple repeats and potential peptide coding regions that can
form a complex network of regulatory elements for sar promoter activation (2, 6). In prior studies, we demonstrated that
the level of SarA, the major sar regulatory molecule (6, 16),
correlates with the extent of agr activation (15). Because of the
complexity of the sar promoter region, we speculated that a
regulatory protein(s) likely binds to the region to modulate
SarA expression. Deletion analysis has implicated the P3-P1
interpromoter region to play an essential role in down-regulating P1 transcription and hence SarA expression during the
growth cycle (6, 27). Based on these studies, we speculate that
the P3-P1 interpromoter region may serve as a binding site for
a repressor protein (27). Curiously, the region upstream of the
P1 promoter but downstream of the P3 promoter is homologous with another AT-rich region upstream of the P2 promoter
(Fig. 1A). Accordingly, we previously partially purified from
crude cell lysates a ⬃12-kDa protein (SarR) with a DNAspecific column containing a sar P2 promoter fragment (27). In
this study, we have significantly extended the characterization
of the SarR protein by characterizing the gene, revealing its sar
promoter binding activity, and analyzing its binding sites on the
sar promoters. More importantly, a mutation in sarR led to
increases in sar P1 (Fig. 7A) and combined P2-P3-P1 (native)
(Fig. 7B) promoter activities. The result of such a mutation is
an increase in SarA expression and subsequent activation of
agr, a major sar target gene, thus justifying the premise that
SarR is a DNA binding protein that down-regulates SarA
expression.
Using the N-terminal sequence of the crudely purified SarR
protein and the availability of a partial amino acid sequence
from the S. aureus genome (TIGR), we were able to amplify
part of the sarR gene with degenerate oligonucleotides and
thus generate a probe to screen for a pACYC177 plasmid
clone containing the intact sarR gene. The SarR protein was
found to have a small molecular size (13.7 kDa), a deduced
basic pI (9.8), and a predominance of charged amino acid
(34%) all features consistent with a DNA binding protein. Gel
shift and footprinting assays indeed confirmed the DNA binding activity of SarR to the sar promoter regions. Secondary
structure analysis with the PHD program (37) revealed that
SarR consists primarily of ␣-helices (75%), which implies a
single-domain structure. A homology search revealed that
SarA is homologous to the entire SarR protein, with 51%
similarity between the two. Interestingly, the homology is relatively global (Fig. 1C). Whether SarA and SarR belong to a
new family of regulatory proteins that do not possess the classic
DNA binding motifs (e.g., helix-turn-helix and leucine zipper)
is entirely speculative. Nevertheless, the region from residues
54 to 77 of SarA, which shows homology with the corresponding region of SarR, also has sequence similarity to the DNA
binding domain (residues of 175 to 198) of VirF, a positive
transcriptional regulator of virulence genes in Shigella flexneri
(13, 18).
The binding site of SarR on the 49-bp fragment derived from
the sar P2 promoter in pUC18 has been determined to be a
28-bp AT-rich sequence (nt 81 to 108) (2) situated 12 bp
upstream of the P2 ⫺35 promoter box (Fig. 5A). The footprinting reaction appeared to be specific because the adjacent
GC-rich region from pUC18 was not protected by SarR. In a
previous study, we speculated that a 7 to 8-bp sequence (TA
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ATTAA), repeated eight times in both sense and nonsense
strands throughout the sar promoter region, may serve as a
binding site for a DNA binding protein. Despite a high AT
content, this motif is found only once within a 6-kb sequence of
agr. In examining the 28-bp SarR binding site on the P2 promoter, this motif was found twice (underlined in Fig. 5A).
Likewise, the motif was also found in the SarR-protected sites
of the sar P1 (underlined in Fig. 5B) and P3 (legend to Fig. 5)
promoter regions. However, unlike that of the P2 promoter,
this motif was found only once within the SarR binding site on
the sar P1 promoter (nt 576 to 583). Remarkably, this 8-bp
sequence was found within an inverted repeat region (nt 553 to
593), previously thought to be essential to the repression of P1
transcription (27). More importantly, SarR binds to this inverted repeat region within the sar P1 promoter. Using synthesized and end-labeled 8-bp fragment (TAAATTAA) and
SarR in gel shift assays, we did not detect any binding of this
sequence motif to SarR. We surmise that the fragment may be
too small to preserve a binding site, since a 34-bp sequence (nt
567 to 600) (2) upstream of the P1 promoter but containing the
8-bp sequence did bind to SarR (reference 27 and unpublished
data). The presence of multiple binding repeats would be consistent with the laddering pattern as observed in gel shift assays
of SarR with the sar P1, P2, and P3 promoters (Fig. 4). However, given the abundance of shifted bands (Fig. 4) relative to
binding sites on the sar P1, P2, and P3 promoters, SarR may
bind to these sites in multimers as well. Given the observations
that the SarA protein can exist in dimer form (36) and that
SarR is homologous with SarA, it is also conceivable that
heterodimers of SarA and SarR can bind to the sar promoters
to elicit the binding pattern that we have repeatedly observed
in gel shift assays of whole-cell extracts with sar promoter
fragments (unpublished data).
The effect of SarR on sar-related transcription in S. aureus is
complex. The complexity arises from the observation that multiple regulatory proteins likely bind to the sar promoter region.
For instance, SigB, a stress-induced transcription factor, binds
to the sar P3 promoter upstream of P1, resulting in activation
of P3 (30) and an associated decrease in P1 expression (1, 7,
27). Likewise, SarA also binds to its own promoter (reference
27 and unpublished data). Finally, recent inquiry into the S.
aureus genome (at TIGR) hints at the presence of other SarA
homologs. Thus, SarR likely represents a series of proteins that
bind to the sar promoter to modulate SarA expression in S.
aureus. The multiplicity of regulatory proteins that likely bind
to the sar promoter implies that the correlation of sarR expression to the activation of individual sar promoters, being more
complex, is less likely to be linear. Despite these complexities,
our studies clearly indicate that one of the major effects of
SarR is to down-modulate sar P1 transcription from the strongest sar promoter (2, 27). This premise is supported by several
findings: (i) an augmentation in sar P1 promoter activity by
FACS; (ii) an enhancement in sar P1 activity toward the postexponential phase in the sarR mutant as documented by a
more quantitative fluorescence-based assay; and (iii) a notable
increase in sar P1 activity in the sarR mutant during the postexponential phase, at a time when SarR expression is normally
maximal in the parental strain (Fig. 7A and 6C).
Although SarR has been shown to bind to the sar P3 and P2
promoter regions by gel shift and footprinting assays, the spe-
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cific effect of this protein on the sar P3 and P2 promoters (i.e.,
increase or decrease in promoter activation during various
growth phases) is less clear. In particular, we could not establish any significant differences in P3 promoter activity during
the growth cycle between the isogenic pair, using both FACS
and a more sensitive and quantitative fluorescence spectrophotometric assay. We reported previously that a decrease in P3
promoter activity, as found in a sigB mutant, was associated
with a concomitant increase in sar P1 promoter activity and
hence elevated SarA expression (7). It is thus tempting to
speculate that SarR, with its maximal expression concurring
with peaked SigB activity during the postexponential phase,
may influence sar P3 promoter and hence down-regulate the
P1 promoter downstream (Fig. 1A and 7A), possibly by virtue
of a partial promoter occlusion as has been observed in E. coli
(1).
The effect of SarR on the combined or native sar promoter
driving SarA expression was also found to be down-regulatory,
as confirmed by increased P2-P3-P1 fusion activity in the sarR
mutant compared with the parent (Fig. 7B). Contrasting with
the downward trend of the P1 sample in the parental strain
(Fig. 7A), the activity of the combined or native sar promoter
in the parental strain increased as the cells transitioned to
stationary phase. As P1 is the predominant sar promoter, these
data also implied that the sequence upstream of the P1 promoter (i.e., P3 and/or P2) in the parental strain probably plays
an important role in up-regulating P1 promoter activity. However, the exact manner in which they contribute to the increase
in P1 activity as the cell cycle progresses is not clearly defined.
Thus, the main effect of the SarR protein is likely to downmodulate the combined sar P2-P3-P1 promoter activity, probably via an effect on the sar P1 promoter. The heightened
increase in the combined promoter activity during the postexponential phase in the sarR mutant also hints at the effect of
unopposed activator(s) in the absence of SarR. The candidate
activators include SarA (27), and possibly other SarA homologs, acting either alone or in combination.
Thus, the major effect of SarR on binding to the sar promoter is a reduction in P1 and in the combined (P2-P3-P1) sar
promoter activity, thus leading to a decrease in SarA protein
expression, preferentially in the late log and stationary phases.
This argument was bolstered by our immunoblot studies in
which we demonstrated that a sarR mutant expressed a higher
level of SarA than its parental counterpart in mid-log, late-log,
and stationary-phase cells (Fig. 8A). Interestingly, maximal
SarA expression in the isogenic pair was observed during the
late log rather than stationary phase. With the parental strain,
the decrease in SarA expression during the stationary phase
may be paritally explained by maximal SarR expression. In the
case of the sarR mutant, we speculated that proteolytic processing (27, 35) or other unknown factor(s) may serve to decrease SarA protein expression during the stationary phase.
Because of the structural complexity of the sar promoter
region (2, 27), it seems logical to surmise that activator and
repressor proteins likely bind to the sar promoter to modulate
the expression of SarA, the major sar regulatory molecule.
Recent transcriptional fusion studies suggested that SarA is
auto regulatory (27), with SarA likely to be an activator for its
own expression (27). In contrast, activation of SigB likely leads
to a down-regulation in SarA expression (7). The combination
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of activator (SarA) and down-modulators (SigB and SarR) for
SarA expression argues for the complex interaction between
regulatory proteins and the sar promoter to modulate downstream genes.
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